top of page


Ceritinib was the first of the 2nd generation TKIs developed by Novartis.  The recommended dose is 750mg daily. A small number of patients will still be taking Ceritinib. Alectinib was approved in August 2018 and this became the preferred drug for newly diagnosed patients.


Anyone with lungs can get lung cancer.

bottom of page